Rational design and synthesis of a novel, selective class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 quaternary lactam dipeptide surrogates

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 18, 1997, Pages 2421-2426

  Semple, J Edward ^a   Minami, Nathaniel K ^a   Tamura, Susan Y ^a   Brunck, Terence K ^a   Nutt, Ruth F ^a   Ripka, William C ^a  

^a Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBIN INHIBITOR;

ARTICLE; CHIRALITY; DRUG DESIGN; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MOLECULAR MODEL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0030766682     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00446-0     Document Type: Article

References (35)

1. Dedicated with genuine affection and respect to Professor Madeleine M. Joullie, Department of Chemistry, University of Pennsylvania, on the occasion of her 70th birthday.
2. (a) Tucker, T. J.; Lumma, W. C.; Mulichak, A. M.; Chen, Z.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, R.; Freidinger, R. M., Kuo, L.C. J. Med. Chem. 1997, 40, 830.
3. (b) Dominguez, C.; Carini, D. J.; Weber, P. C.; Knabb, R. M.; Alexander, R. S., Kettner, C. A.; Wexler, R. R. Bioorg. Med. Chem. Lett. 1997, 7, 79.
4. (c) Wiley, M. R.; Chirgadze, N. Y.; Clawson, D. K.; Craft, T. J.; Goifford-Moore, D. S.; Jones, N. D.; Olkowski, J. L.; Weir, L. C. Smith, G. F. ibid. 1996, 6, 2387.
5. (d) Costanzo, M. J.; Maryanoff, B. E.; Hecker, L. R.; Schott, M. R.; Yabut, S. C.; Zhang, H.-C.; Andrade-Gordon, P.; Kauffman, J., A.; Lewis, J. M.; Krishnan, R.; Tulinsky, A. J. Med. Chem. 1996, 39, 3039.
6. Recent reviews: (a) Ripka, W. C. Curr. Opin. Chem. Biol. 1997, 1/2, in press.
7. (b) Ripka, W. C.; Vlasuk G. P. In Ann. Rep. Med. Chem. Bristol, J. A., Ed.; Academic: San Diego, 1997; Vol. 32, in press.
8. (c) Edmunds, J. J.; Rapundalo, S. T.; Siddiqui, M. A. ibid., 1996, Vol. 31, 51.
9. (d) Scarborough, R. M. ibid. 1995; Vol. 30, 71.
10. (e) Lyle, T. A. Perspectives in Drug Discovery and Design 1993, 1, 453.
11. (a) Semple, J. E.; Rowley, D. C.; Brunck, T. K.; Ha-Uong, T.; Minami, N. K.; Owens, T. D.; Tamura, S. Y.; Goldman, E. A.; Siev, D. V.; Ardecky, R. J.; Carpenter, S. H.; Ge, Y.; Richard, B. M.; Nolan, T. G.; Håkanson, K; Tulinsky, A.; Nutt, R. F.; Ripka, W. C. J. Med. Chem. 1996, 39, 4531.
12. (b) Semple, J. E.; Ardecky, R. J.; Nutt, R. F.; Ripka, W. C.; Rowley, D. C.; Lim-Wilby, M. S.; Brunck, T. K. PCT Patent Application WO 95/35311, 1995. (Chem Abstr. 1996, 124: 261754)
13. (c) Tamura, S. Y.; Goldman, E. G.; Brunck, T. K.; Ripka, W. C.; Semple, J. E.; Bioorg. Med. Chem. Lett. 1997, 7, 331.
14. For syntheses and applications of quaternary lactam systems to other drug candidates see (a) Colombo, L.; Di Giacomo, M.; Scolastico, C.; Manzoni, L.; Belvisi, L.; Molteni, V. Tetrahedron Lett. 1995, 36, 625.
15. (b) Thaisrivongs, S.; Pals, D. T.; Turner, S. R.; Kroll, L. T. J. Med. Chem. 1988, 31, 1369.
16. (c) Zydowsky, T. M.; Dellaria, J. F.; Nellans, H. N. J. Org. Chem. 1988, 53, 5607.
17. (a) Tamura, S. Y.; Semple, J. E.; Reiner, J. E.; Goldman, E. A.; Brunck, T. K.; Lim-Wilby, M. S.; Carpenter S. H.; Rote, W. E.; Oldeschute, G. L.; Richard, B. M.; Nutt, R. F.; Ripka, W. C. Bioorg. Med. Chem. Lett. 1997, 7, 1543.
18. (b) Tamura, S. Y.; Semple, J. E.; Ripka, W. C.; Ardecky, R. J.; Carpenter S. H.; Ge, Y.; Brunck, T. K.; Nutt, R. F. PCT Patent Application WO 96/18644 A1, 1996 (Chem Abstr. 1996, 125: 143331).
19. All new compounds were characterized by full spectroscopic (NMR, low/high resolution MS) data. Yields refer to spectroscopically and chromatographically homogenous (≥95% by HPLC, TLC) materials.
20. (a) Cheng, H.; Keitz, P.; Jones, J. B. J. Org. Chem. 1994, 59, 7671.
21. (b) Karady, S.; Amato, J. S.; Weinstock, L. M. Tetrahedron Lett. 1984, 25, 4337.
22. (c) cf.: Smith, A. B.; Guzman, M. C. Sprengeler, P. A.; Keenan, T. P.; Holcomb, R. C.; Wood, J. L.; Carroll, P. J.; Hirschmann, R. J. Am. Chem. Soc. 1994, 116, 9947.
23. (a) Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. J. Org. Chem. 1996, 61, 3849.
24. (b) Abdel-Magid, A. F.; Harris, B. D.; Maryanoff, C. A. Synlett 1994, 81.
25. (a) Tamura, S. Y.; Semple, J. E.; Ardecky, R. J.; Leon, P.; Carpenter, S. H.; Ge, Y.; Shamblin, B. M.; Weinhouse, M. I.; Ripka, W. C.; Nutt, R. F. Tetrahedron Lett. 1996, 37, 4109.
26. (b) Webb, T. R.; Reiner, J. E.; Tamura, S. Y.; Ripka, W. C.; Dagnino, R.; US Patent 5514777, 1996 (Chem Abstr. 1996, 124: 261752).
27. (a) Freidinger, R. M.; Perlow, D. S.; Veber, D. F. J . Org. Chem 1982, 47, 104.
28. Furthermore, to unambiguously determine the stereochemistry of this family, we are currently pursuing the asymmetric synthesis of the proposed active (R)-isomer 2b via chiral cis-oxazolidine intermediates, employing variations of the chemistry described in Scheme 1. The results from this approach will be reported in due course.
29. (a) Carpino, L. A.; El-Faham, A.; Albericio, F. Tetrahedron Lett. 1994, 35, 2279.
30. (b) Carpino, L. A. J. Am. Chem. Soc. 1993, 115, 4397.
31. Rittle, K. E.; Evans, B. E.; Bock, M. G.; Di Pardo, R. M.; Whitter, W. L.; Homnick, C. F.; Veber, D. F.; Freidinger, R. M. Tetrahedron Lett. 1987, 28, 521.
32. The in vitro enzyme assays were performed according to the protocols described in ref 4a.
33. (a) Engh, R. A.; Brandstetter, H.; Sucher, G.; Eichinger, A.; Baumann, U.; Bode, W.; Huber, R.; Poll, T.; Rudolph, R.; von der Saal, W. Structure 1996, 4, 1353.
34. (b) Malley, M. F.; Tabernero, L.; Chang, C. Y.; Ohringer, S. L.; Roberts, D. G. M.; Das, J.; Sack, J. S. Protein Sci. 1996, 5, 221.
35. (c) Håkansson, K.; Tulinsky, A.; Abelman, M. M.; Miller, T. A.; Vlasuk, G. P.; Bergum, P. W.; Lim-Wilby, M. S. L.; Brunck, T. K. Bioorg. Med. Chem. 1995, 3, 1009.